Florence Cymbalista

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 612 citations · Full text

Medicine, Hematology, Pharmacology +10

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Barbara Eichhorst, Tadeusz Robak, Emili Montserrat et al. · Annals of Oncology · 2020 · 568 citations · Full text

Medicine, Hematology, Immunology +14

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W. Flinn, Peter Hillmen, Marco Montillo et al. · Blood · 2018 · 341 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien et al. · Haematologica · 2017 · 258 citations · Full text

Medicine, Oncology, Pharmacology +15